The invention provides branched trialkylamine oxides with improved properties. The trialkylamine oxides of the invention produced from branched trialkylamines, in one embodiment, can be made using certain branched C10-12 enals and aldehydes. The invention also provides an trialkylamine oxide having the formula:

##STR00001##

wherein R5, R6 and R7 are independently at least one of C3H7, C2H5, CH3, or H, or mixtures thereof; and wherein R5 and R6 are not H at the same time. In one embodiment, the trialkylamine oxides of the invention can be useful in making various products, for example, as surfactants.

The invention provides branched hydrophobes for the production of surfactants with improved properties over linear hydrophobes. The invention also provides branched C10-12 enals and aldehydes that are oxidized to branched fatty acids or hydrogenated to branched fatty alcohols and further derivatized to surfactants, through ethoxylation or esterification and other or subsequent reactions. The invention further provides surfactants made from the branched trialkylamine intermediates, including amphoteric, cationic and nonionic surfactants.

The invention provides branched hydrophobes for the production of surfactants with improved properties over linear hydrophobes. The invention also provides branched C.sub.10-12 enals and aldehydes. The invention additionally provides branched C.sub.10-12 enals and aldehydes that are oxidized to branched fatty acids or hydrogenated to branched fatty alcohols and further derivatized to surfactants, through ethoxylation or esterification and other or subsequent reactions. The enals and aldehydes are useful in making branched trialkylamine intermediates useful in making certain surfactants, including amphoteric, cationic and nonionic surfactants. The surfactants which can be produced from the trialkylamine intermediates include the quaternary ammonium compounds of the invention. The quaternary ammonium compounds of the invention are also useful in making the branched enals and/or aldehydes useful in the invention.

The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas:

##STR00001##

wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas:

##STR00001##

wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G.sup.1, G.sup.2, G.sup.3, L.sup.1, L.sup.2, and L.sup.3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

##STR00001##

Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G.sup.1, G.sup.2, G.sup.3, L.sup.1, L.sup.2, and L.sup.3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

##STR00001##

Certain embodiments are directed to compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ER? selective and/or ER? specific ligands.

Certain embodiments are directed to compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ER? selective and/or ER? specific ligands.

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.